Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Great thing about that RJ group is that they already have huge contracts with the big commercial truck and power train manufacturers… once these motors are tested and in production it’s a straightforward transition for them to deal with manufacturers and start selling these.
That’s one of the things I talked to the CEO about when we talked a couple weeks ago
I talked to the CEO Reggie Fubara … very personable and extremely motivated to move this forward
Talked about the new power plant/engine their patents and goal to have it in a truck by Dec. this yr.
Also about goal moving forward to have new IR & PR in place for HYORC
SRE has revenue and is continuing to work on their ongoing projects.
just a little info … to help maintain positive view of what’s happening and will happen in future.
😊
lol yes … I meant RS … not RM
Yes you are right they will use those shares for financing and maybe other mergers in future …. They added those shares to the structure for a reason … can’t see a RS happening
Anyone talk to this person
Laura Donohoe
Investor Relations
Telephone: +1 (281) 532-9034
Got a strong feeling that these shares at .12 will history soon and are real bargain here …. If anyone wants anymore now is the time to get a few …. IMO
Float will stay same and the rest will be restricted for 1 yr after uplist ….🤞
Yup …. With only 26.3 million in the float at DTC … that pretty tight structure 😁
Well there we go …. .10 cent on 100k shares deal must be gettin close to being signed
35k so far today … with full new website coming soon it should really go
New interim website is up … www.srepower.com
Enjoy
Audits done for 2018 to 2021 … now we see what happens next , hopefully announce the the completion of the merger and name change
Just so everyone knows Pcaob audits done ... that's about a 20k cost ... these guys are serious
ASPZ Provides an Update on the HyOrc Technology Development Plans
https://www.otcmarkets.com/stock/ASPZ/news/ASPZ-Provides-an-Update-on-the-HyOrc-Technology-Development-Plans?id=446063
ASPZ Provides an Update on the HyOrc Technology Development Plans
Ah …. Well from what I can understand the Pcaob is being worked on or may be done… well see how things look when all that is fone
I think that’s main board …. I thought small cap was 2 … I could be wrong . Either way it’ll be fine
Lookin/hopin for .20+ here soon … and $2 once we go Naz
Also with the PCAOB AUDIT AND this New Company and board … we will be looking at Nazdaq
HyOrc Executive Summary
The HyOrc hydrogen engine is currently the only affordable & sustainable zero emissions solution available for decarbonising the $350bn global HGV market, which is currently being powered exclusively by diesel engines.
Engine
We have developed a revolutionary, affordable, efficient & durable heavy-duty vehicle engine powered by a combination Of Hydrogen Gas & our patented Organic Rankine Cycle (ORC) Turbine.
The HyOrc engine is manufactured at a much lower cost, offers higher durability & enjoys lower O&M costs than hydrogen fuel cells.
The HyOrc engine doesn’t require the already rare & dwindling supply of sophisticated conflict minerals that EVs require.
This guy will be on board of directors. Former Cheif Technology Office at Hyzon motors
https://theorg.com/org/hyzon-motors/org-chart/shinichi-hirano
Yup … and look at those name involved… cool
New PR coming out regularly now …. Very nice
TAMPA, FL / ACCESSWIRE / August 16, 2023 / EV Biologics Corp, OTC PINK:YECO, today announced that it has completed production of a next-generation, "Gen-2", MSC exosome-based therapeutic product.
Rigorous product analysis has already begun, and the Company has engaged leading independent testing laboratories to perform sophisticated analyses of molecular composition, therapeutic activity, and any potential forms of contamination, to thoroughly validate the product and prepare comprehensive product data specifications that are second to none.
CEO, Daniel Mckinney said: "As stated, creating novel regenerative medicines to promote health and longevity is our top priority - essentially, our goal is to produce the ‘Fountain of Youth'. Most biotech companies only engage in endless rounds of research and development. We now have a product that we intend to start using in clinical trials in Asia, the Middle East and in South America. There is now hope for old age, frailty, and a host of other illnesses with this revolutionary product. "
This is good news … $2 min to uplist to Naz … "we intend to re-apply to up-list to Nasdaq as soon as possible." New PR
Amazing how a 1 mil float stock moves on so few shares … ??
One thing to be said … still 1 mil float so it can go quick
Yes nice news … just gotta wonder though $100 mil value on Excyte … based on what … research patents … I don’t see any
This has sat for months with barely a trade … needs to be more than just PRs … can say anything you want in those
Go back for 2yrs and look at all the PRs so many things said and promised none have come to fruition … other than a lot of people bought in the $2 to $6 range … I think some are getting out lots of sells today
Ya … pretty sad
EV Biologics Signs MSA with LONZA Cell & Gene Therapy
Press Release | 05/17/2022
HOUSTON, TX / ACCESSWIRE / May 17, 2022 / EV Biologics Corp, OTC PINK:YECO, today announced that it has signed a Manufacturing Services Agreement (MSA) with Lonza for development of stem/progenitor cell-derived nanotherapeutics and scalable biomanufacturing process.
The MSA enables EV Biologics to accelerate its nanotherapeutic biomanufacturing process and producer-cell line development through Lonza's global infrastructure and deep expertise in cell and gene therapy.
EV Biologics has been developing nanotherapeutic-producer cells and optimizing a process for isolation of primary cells from tissue and expansion of cell banks using defined cell culture conditions. The Company is very pleased to announce that advancing its relationship with Lonza will accelerate development and implementation of rigorous upstream and downstream biomanufacturing processes that will facilitate production of more consistent nanotherapeutic candidates.
CEO, Daniel Mckinney, said "We are very excited to enter the next phase of our business relationship with Lonza, the world's premier biomanufacturing firm for further process development. This represents a significant step toward our goal of developing high-quality nanotherapeutics for a broad range of clinical conditions. Furthermore, we are maximizing our resources and multiplying our efficiency by leveraging the assets of best-in-class partners like Lonza, rather than investing tens of millions in our own physical infrastructure for laboratory and manufacturing facilities."
About the Company
EV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, developing a range of nanotherapeutics to substantially enhance the intrinsic bioactivity of stem and progenitor cell-derived nanoparticles. The Company is also developing biomanufacturing, bioinformatic and bioengineering innovations to optimize production of nanoparticle therapeutics and biologics. These versatile therapeutic platforms will enable generation of nanotherapeutics targeting a broad range of regenerative medicine and longevity applications.
About Lonza
Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. They focus on enabling treatments that prevent illness and support healthier lifestyles. They optimize scientific innovation and manufacturing technology to enable our customers to serve their patients and consumers.
They provide a wide range of services and products from early phase discovery to custom development and manufacturing of active pharmaceutical ingredients to innovative dosage forms for the pharma and consumer health and nutrition industries. Their scale and resources mean they can provide a one-stop solution for our customers to help people get well, feel well, and stay well. In 2021, we supported more than 780 preclinical and clinical small and large molecules, more than 245 commercial small and large molecules and produced around 250 billion capsules.
Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 16,000 employees (full-time equivalent), they comprise high-performing teams
and individual talent that make a meaningful difference to their own businesses, as well as to the communities in which they operate. Their business benefits from global supply chains, but have worked to maintain the agility to address marketplace needs on a local level.
A firm commitment to responsible business and sustainability underpins everything they do. Minimizing their impact on the environment, conserving energy and natural resources, and helping to improve life quality are all central to our culture. Lonza's Vision Zero initiative is a prime example, as they strive to achieve zero workplace accidents and injuries, zero environmental incidents, zero product transportation incidents and zero manufacturing process incidents. They work to attract and retain the best talent, to make a meaningful difference to their own business, as well as to the communities in which they operate.
Lonza generated sales of CHF 5.4 billion with a CORE EBITDA of CHF 1.7 billion in Full-Year 2021. The Lonza shares are listed on the SIX Swiss Exchange and Swiss Market Index (SMI). They also maintain a secondary listing on the SGX Singapore Exchange. For more information about Lonza: www.lonza.com
Looks like nothing about supposed gold deal and more people are giving up .. same old same old
Yup have to say I agree slojab … NFT piece of crap … pretty sad what’s happened here all these PRs and no follow through
It’s as if they think people are gonna buy something like that Why?
Or … it could be something as simple as … someone with a bunch of shares sees some volume and decides they will get out …. For every seller there’s a buyer so someone is taking the shares … lol
Well something is happening… volume is more than last 3months combined
No news yet but something gotta be coming
ASPZ current pink again …. About time being as how Q3 was submitted Nov 24
Now we just need some news
Something is up … 342k today mostly buying
NASHVILLE, TN / ACCESSWIRE / October 28, 2021 / EV Biologics Corp, OTC Pink:YECO, today updated shareholders about a recent publication authored by its Chief Medical Officer, Dr. Jason Sanders.This review discusses some of the cellular and molecular pathology of COVID-19 and the relevant therapeutic mechanisms of small extracellular vesicles (EVs), such as exosomes, in Acute Lung Injury (ALI). The original manuscript was initially prepared by Dr. Sanders in March 2020, near the beginning of the pandemic, to illustrate the therapeutic potential of mesenchymal stem cell (MSC) exosomes in this type of disease. Since that time, a number of clinical trials investigating MSC exosomes as a therapy for COVID-19 have been initiated.Please download the article: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8225928/.CMO Dr. Jason Sanders said: "This publication presents only a very small fraction of the potential of EV-based therapeutics produced by MSCs and other stem cells. Through convergence of multiple revolutionary technologies, we are advancing our objectives to capture the remarkable therapeutic potential of MSCs, to optimize it for a breadth of focused clinical applications, and to standardize the products and processes for preparation of next-generation therapeutics."EV Biologics is developing optimized clonal stem cell lines for biomanufacturing of naïve and engineered EV-based therapeutics that will be developed into biological drugs seeking FDA approval for several different clinical indications: acute lung injury (eg. COVID-19, influenza, acute respiratory distress syndrome), autoimmune (lupus, multiple sclerosis, rheumatoid arthritis, etc) and systemic inflammatory syndromes, osteoarthritis and other degenerative musculoskeletal disease, neurodegenerative conditions, metabolic diseases, and other age-related conditions.CEO Daniel Mckinney, said "EV Biologics has adopted a very advanced technological approach to biopharmaceutical development that will rapidly develop and efficiently manufacture EV-based therapeutics within a rigorous cGMP framework to prepare investigational new drugs, far superior to anything currently on the market, for submission to FDA. Our audacious goal is to conquer incurable diseases and revolutionize modern medicine to deliver better health for patients worldwide."About the CompanyEV Biologics (formerly Yulong Eco-Materials Limited) is a Wyoming, USA domiciled Biotechnology Company, intent on developing and enhancing the intrinsic therapeutic activity of mesenchymal stromal cell (MSC) secreted factors, as well as targeted delivery of bioactive molecules using engineered exosomes. The company is working to optimize cell lines for production of native bioactive nanoparticles and to establish an exosome engineering platform to enhance specific therapeutic activity. Initially, these novel regenerative products will be produced for preclinical research on a number of clinical indications. Using proprietary and patentable technologies, the Company is creating exclusive IP and IT inherent in thesebioengineered products. Further product development will be focused on investigation of novel stem cell-derived biopharmaceuticals designed for specific clinical conditions.Forward-Looking StatementsThis news release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.YECO has 7.22 million shares issued and outstanding with a float of 1,016,375 shares.Contact:Dennis BurnsInvestor RelationsTel(567)237-4132dburns@nvestrain.comFor more information on EV Biologics please visit: www.evbiologics.comSOURCE: EV Biologics Corp,View source version on accesswire.com: https://www.accesswire.com/670115/EV-Biologics-Chief-Medical-Officer-Publication-on-COVID-19-Exosomes
Finally … we got our yield removed … we are now Pink current